KRRO
Korro Bio, Inc.8.22
+0.26+3.27%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
77.41MP/E (TTM)
-Basic EPS (TTM)
-9.42Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
CFO resigns; CEO takes interim role
Korro Bio's CFO Vineet Agarwal resigned on October 7, 2025, effective October 17, to chase another opportunity, with no disagreements on operations. He'll advise for 30 days at $300/hour while receiving $352,500 in severance plus a $149,400 prorated bonus, COBRA support for nine months, and extended stock option exercise to March 31, 2027. CEO Ram Aiyar steps in as interim CFO without extra pay. Smooth handover eases the shift, yet leadership overlap tests bandwidth.
10-Q
Q2 FY2025 results
Korro Bio posted collaboration revenue of $1.5 million in Q2 FY2025 ended June 30, 2025, up from zero a year earlier, thanks to its Novo Nordisk deal, while research and development expenses climbed 22.7% y/y to $21.0 million, driven by KRRO-110 clinical trial costs and rare metabolic program advances. This fueled an operating loss of $27.2 million, 12.8% wider y/y, and a net loss of $25.8 million or $2.74 per diluted share on 9.4 million shares, versus $21.8 million or $2.43 last year. Cash burn quickened to $43.7 million for the half, leaving $119.6 million in cash and marketable securities at quarter-end, funding operations into 2027. The May workforce cut of 19% aims to streamline amid KRRO-110's Phase 1/2a progress, with no major M&A or debt. Clinical trial delays remain a key risk.
8-K
Korro advances AATD trial
Korro Bio advanced its Phase 1/2a REWRITE trial for KRRO-110 in Alpha-1 Antitrypsin Deficiency, dosing over 80% of planned healthy volunteers with no serious adverse events observed. The EMA granted orphan drug designation, bolstering development incentives alongside FDA approval. Cash stood at $119.6 million, funding operations into 2027, while net loss widened to $25.8 million amid rising R&D spend. Interim data arrives soon.
AKRO
Akero Therapeutics, Inc.
54.65+0.00
ATXS
Astria Therapeutics, Inc.
12.87-0.05
BLTE
Belite Bio, Inc
149.13+6.60
CRSP
CRISPR Therapeutics AG
55.97-0.28
KALA
KALA BIO, Inc.
0.56-0.05
KLTO
Klotho Neurosciences, Inc.
0.39+0.01
KROS
Keros Therapeutics, Inc.
21.53+0.30
KTTA
Pasithea Therapeutics Corp.
1.14-0.02
NTLA
Intellia Therapeutics, Inc.
9.12-0.02
WVE
Wave Life Sciences Ltd.
16.41+0.30